Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The response includes a label-supported statement about increased risk of serious infections, but it also asserts malignancy risk without sufficient FDA label excerpt support for malignancy in the provided text.
Category Scores
Accurate Statements
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death.
Label Section 5.1 (Serious Infections): “Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death.”
Unsupported Statements
HUMIRA increases risk of serious infections and malignancy.
The provided label excerpts include support for serious infections (Section 5.1) but do not include the boxed “Malignancy” warning text or any malignancy-specific labeled section content; malignancy support cannot be verified from the supplied excerpts.
Contradictions
Important Omissions
FDA label-evidenced malignancy risk language (e.g., boxed “Malignancy” warning and/or relevant malignancy section) was not provided in the excerpt set used for evaluation, yet the combined malignancy claim was asserted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Serious infection risk is supported by the label excerpt, but malignancy risk was included without verifiable label excerpt support, reducing reliability of the safety statement as presented.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Malignancy risk is asserted without label excerpt support for malignancy in the provided text.
Suggested Improvement
Limit the claim to the portion supported by the provided excerpts (increased risk of serious infections per Section 5.1) or include the malignancy-specific boxed warning/section text to substantiate the malignancy risk claim.